---

---

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

Date of Report: May 19, 2015
Commission File Number: 001-36891

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ⊠ Form 40-F ⃞

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ⃞

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ⃞

---

---

EXHIBIT INDEX

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

3

Exhibit 99.1

Cellectis SA Combined General Shareholders’ Meeting of May 18, 2015

PARIS--(BUSINESS WIRE)--May 19, 2015--Regulatory News:

The Combined General Shareholders’ Meeting of Cellectis S.A. (Paris:ALCLS) (Alternext: ALCLS – Nasdaq Global Market: CLLS) was held on Monday, May 18, 2015 in Paris, at the Group’s headquarters.

At the end of the meeting, during which more than 75% of votes were exercised, all of the ten resolutions submitted for the shareholders' vote were approved.

In particular, Cellectis’ shareholders voted on:

• the approval of the parent company and consolidated financial statements for the fiscal year ended December 31, 2014;
• term of office renewal of directors Mr André Choulika, Mr David Sourdive and Mr Alain Godard;
• the approval of regulated agreements;
• the authorization of a share repurchase plan and the authorization given to the Board of Directors to retire the shares acquired through it;
• the nomination of a new Director, Mr Jean-Marie Messier.

Jean-Marie Messier, 58 years old, is co-founder and head of Messier Maris & Associés, an investment bank headquartered in Paris and New-York. Messier Maris & Associés is recognized as a leading independent corporate finance advisor in mergers and acquisitions, financial restructuring and equity / debt advisory.

The full results of the vote can be examined on the company’s website (www.cellectis.com).

About Cellectis

Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com

CONTACT:
Media contact
Jennifer Moore, Director of Communications
Phone: 917-580-1088
email: media@cellectis.com
or
BMC Communications
Brad Miles
Phone: 646-513-3125
email: bmiles@bmccommunications.com
or
IR contact
Simon Harnest, VP Finance and Investor Relations
Phone: 646-385-9008
email: simon.harnest@cellectis.com